Biological Therapies for the Management of Enteric Disease: Considerations for the Clinician.
Adam SalehUsman AnsariShaadi AbughazalehKerri GlassnerBincy P AbrahamPublished in: Biologics : targets & therapy (2022)
Several biologic therapies have been approved for enteric diseases. We evaluate each biologic's role based on their mechanism of action in treating these conditions. This review examines data on efficacy and safety, as well as considerations for using these therapies in clinical practice in inflammatory bowel diseases, enteric infections-specifically Clostridioides difficile colitis-and potentially in the increasingly prevalent disorder of eosinophilic esophagitis. When choosing an appropriate therapy, it is important to assess patient severity, as most biologics are approved for those with moderate to severe disease activity. With many years of data from clinical trials and real-world experience, these therapies have been shown to improve outcomes overall in enteric diseases, contributing to more options for our patients.
Keyphrases
- rheumatoid arthritis
- disease activity
- clinical trial
- systemic lupus erythematosus
- clinical practice
- end stage renal disease
- electronic health record
- rheumatoid arthritis patients
- ankylosing spondylitis
- ejection fraction
- newly diagnosed
- chronic kidney disease
- big data
- clostridium difficile
- case report
- juvenile idiopathic arthritis
- randomized controlled trial
- prognostic factors
- machine learning
- high intensity
- stem cells
- drug administration
- weight loss
- patient reported
- deep learning
- double blind
- replacement therapy